The Guardian Australia – Business
·business
·2 hours ago
London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’
London-based Poolbeg Pharma began a trial on POLB 001, an oral drug aimed at preventing cytokine release syndrome in cancer patients, at six NHS hospitals. The trial, involving 30 participants receiving treatment with Johnson & Johnson's teclistamab, could allow outpatient care and reduce costs significantly for the NHS. Interim trial data is expected by summer's.
Summary by Glance · The Guardian Australia – Business
Newer
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI